Fig. 4From: The anti-tumor and renoprotection study of E-[c(RGDfK)2]/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride/salvianolic acid AThe fluorescence staining images of HEK293 cells treated with the preparations after 4Â h (a) and 24Â h (b). A: N.S., B: DOX solution, C: Sal A/DOX solution, D: NLC-Sal A/DOX, E: FA-NLC-Sal A/DOX, F: E-[c(RGDfK)2]-NLC-Sal A/DOX, G: E-[c(RGDfK)2]/FA-NLC-Sal A/DOX. I: Hoechst 33342, II: Rhodamine 123, III: Mitotracker Deep Red FM, IV: The full view of the cellsBack to article page